Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 536Uterine Cervical Neoplasms 249Fallopian Tube Neoplasms 239Endometrial Neoplasms 142Carcinoma, Ovarian Epithelial 135Breast Neoplasms 101Neoplasms 74Carcinoma, Non-Small-Cell Lung 70Colorectal Neoplasms 53Uterine Cervical Dysplasia 49Papillomavirus Infections 49Neoplasm Metastasis 48Pancreatic Neoplasms 46Melanoma 44Uterine Neoplasms 43Prostatic Neoplasms 41Urinary Bladder Neoplasms 40Lung Neoplasms 40Stomach Neoplasms 38Peritoneal Neoplasms 37Recurrence 36Carcinoma, Renal Cell 35Triple Negative Breast Neoplasms 33Head and Neck Neoplasms 32Esophageal Neoplasms 31Small Cell Lung Carcinoma 30Sarcoma 28Vulvar Neoplasms 26Vaginal Neoplasms 24Testicular Neoplasms 22

Interventions

talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Ovarian Cancer × Gynecologic × Clear all
NCT01989546 2021-02-23

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
9 enrolled 11 charts
BreastGynecologicOther solid neoplasm

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡